JP2025013884A5 - - Google Patents

Download PDF

Info

Publication number
JP2025013884A5
JP2025013884A5 JP2024182581A JP2024182581A JP2025013884A5 JP 2025013884 A5 JP2025013884 A5 JP 2025013884A5 JP 2024182581 A JP2024182581 A JP 2024182581A JP 2024182581 A JP2024182581 A JP 2024182581A JP 2025013884 A5 JP2025013884 A5 JP 2025013884A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
foxp3
homology
gene
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024182581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025013884A (ja
JP7844582B2 (ja
Filing date
Publication date
Priority claimed from JP2020560400A external-priority patent/JP7575950B2/ja
Application filed filed Critical
Publication of JP2025013884A publication Critical patent/JP2025013884A/ja
Publication of JP2025013884A5 publication Critical patent/JP2025013884A5/ja
Application granted granted Critical
Publication of JP7844582B2 publication Critical patent/JP7844582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024182581A 2018-04-27 2024-10-18 遺伝子編集されたcd34+細胞におけるfoxp3の発現 Active JP7844582B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862663545P 2018-04-27 2018-04-27
US62/663,545 2018-04-27
JP2020560400A JP7575950B2 (ja) 2018-04-27 2019-04-25 遺伝子編集されたcd34+細胞におけるfoxp3の発現
PCT/US2019/029082 WO2019210042A1 (en) 2018-04-27 2019-04-25 Expression of foxp3 in edited cd34+ cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020560400A Division JP7575950B2 (ja) 2018-04-27 2019-04-25 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Publications (3)

Publication Number Publication Date
JP2025013884A JP2025013884A (ja) 2025-01-28
JP2025013884A5 true JP2025013884A5 (https=) 2025-04-10
JP7844582B2 JP7844582B2 (ja) 2026-04-13

Family

ID=68294731

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560400A Active JP7575950B2 (ja) 2018-04-27 2019-04-25 遺伝子編集されたcd34+細胞におけるfoxp3の発現
JP2024182581A Active JP7844582B2 (ja) 2018-04-27 2024-10-18 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020560400A Active JP7575950B2 (ja) 2018-04-27 2019-04-25 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Country Status (9)

Country Link
US (2) US11713459B2 (https=)
EP (1) EP3784690A4 (https=)
JP (2) JP7575950B2 (https=)
CN (1) CN112218882A (https=)
AU (2) AU2019261438B2 (https=)
CA (1) CA3091688A1 (https=)
IL (1) IL277039A (https=)
SG (1) SG11202007878UA (https=)
WO (1) WO2019210042A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042179A1 (en) 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
CA3091491A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of human foxp3 in gene edited t cells
AU2019261438B2 (en) * 2018-04-27 2024-08-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of FOXP3 in edited CD34+ cells
KR20210116531A (ko) * 2019-01-18 2021-09-27 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 영양 장애형 표피 수포증 치료약
JP2022533713A (ja) 2019-05-21 2022-07-25 サンガモ セラピューティクス, インコーポレイテッド 調節性t細胞における制御された導入遺伝子発現
WO2020264039A1 (en) * 2019-06-27 2020-12-30 Seattle Children's Hospital (dba Seattle Children's Research Institute) Artificial antigen-specific immunoregulatory t (airt) cells
JP2023501388A (ja) 2019-11-08 2023-01-18 サンガモ セラピューティクス, インコーポレイテッド 操作された制御性t細胞の生成
WO2021144692A1 (en) * 2020-01-14 2021-07-22 Crispr Therapeutics Ag Methods for increased efficiency of homology-directed repair
EP4103591A4 (en) 2020-02-13 2024-09-04 The Board of Trustees of the Leland Stanford Junior University Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients
AU2021368557A1 (en) * 2020-10-27 2023-06-08 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
CN112851794B (zh) * 2021-02-04 2023-05-23 苏州铂维生物科技有限公司 一种基于cd271的抗原表位及其应用
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100996016B1 (ko) 2000-09-20 2010-11-22 밀리포어 코포레이션 폴리뉴클레오티드
EP1967525B1 (en) 2001-05-08 2012-11-14 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
GB0614536D0 (en) 2006-07-21 2006-08-30 Metcalfe Susan M Methods of controlling cellular response to LIF
EP2064350B1 (en) * 2006-11-27 2013-01-02 Ludwig Institute for Cancer Research Ltd. Expression of foxp3 by cancer cells
EP2126054B1 (en) 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008101272A1 (en) * 2007-02-21 2008-08-28 Women's And Children's Health Research Institute Inc Method for obtaining treg-cells
US8158596B2 (en) 2007-05-11 2012-04-17 The Regents Of The University Of Michigan Materials and methods for FOXP3 tumor suppression
US8846308B2 (en) 2007-06-08 2014-09-30 The Trustees Of The University Of Pennsylvania Method for identifying immune response modulators
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
TW200942246A (en) 2008-03-03 2009-10-16 Fabio Grassi Method of modulating T cell-dependent immune responses
WO2012018930A1 (en) 2010-08-03 2012-02-09 University Of Miami Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy
WO2014180943A1 (en) 2013-05-08 2014-11-13 Vib Vzw Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015121454A1 (en) 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
AU2015233347A1 (en) 2014-03-21 2016-09-08 Cellectis Engineering mammalian genome using DNA-guided Argonaute interference systems (DAIS)
KR101835554B1 (ko) 2014-06-24 2018-04-19 서울대학교 산학협력단 C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법
CN107250373A (zh) 2015-01-12 2017-10-13 麻省理工学院 通过微流体递送实现的基因编辑
WO2016123578A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
CN107921148A (zh) * 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
US11499168B2 (en) 2016-04-25 2022-11-15 Universitat Basel Allele editing and applications thereof
EP3497221A4 (en) 2016-08-10 2020-02-05 Duke University COMPOSITIONS, SYSTEMS AND METHODS FOR PROGRAMMING IMMUNE CELL FUNCTION BY TARGETED GENE REGULATION
MA45996A (fr) * 2016-08-16 2021-06-02 Bluebird Bio Inc Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
AU2017347854B2 (en) 2016-10-27 2022-12-08 Intima Bioscience, Inc. Viral methods of T cell therapy
CA3042179A1 (en) 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
CN110191955B (zh) 2016-12-13 2024-05-31 西雅图儿童医院(Dba西雅图儿童研究所) 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
CN109790518A (zh) * 2017-05-08 2019-05-21 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
WO2019040655A1 (en) 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
CA3091491A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of human foxp3 in gene edited t cells
AU2019261438B2 (en) * 2018-04-27 2024-08-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of FOXP3 in edited CD34+ cells
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells

Similar Documents

Publication Publication Date Title
JP2025013884A5 (https=)
JP2025013879A5 (https=)
JP2020518276A5 (https=)
CN103224947B (zh) 一种基因打靶系统
JP7844582B2 (ja) 遺伝子編集されたcd34+細胞におけるfoxp3の発現
Li et al. Adenovirus vectors in hematopoietic stem cell genome editing
Di Matteo et al. Recent developments in transposon-mediated gene therapy
JP2025170240A5 (https=)
JP2021518139A5 (https=)
JP2016165307A5 (https=)
US20180163188A1 (en) Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
HK1223401A1 (zh) 用於治疗遗传病状的方法和组合物
JP2020508046A (ja) ゲノム編集システムおよび方法
JP2023533417A5 (https=)
IL295858B1 (en) gRNA molecules including TRACR and crRNA, compositions containing them and their use
JP2018516978A5 (https=)
US12275951B2 (en) Engineered guide RNA and uses thereof
EP3204496A1 (en) Compositions and methods for promoting homology directed repair
JP2021521849A5 (https=)
KR20160059994A (ko) 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법
JP2021520800A5 (https=)
CN113195001B (zh) 重组细小病毒载体及其制备方法和用途
JP2021502077A5 (https=)
JP2022543241A (ja) Huhエンドヌクレアーゼを用いた標的化ゲノム修飾を促進するための方法及び組成物
WO2024158864A1 (en) Mb2cas12a variants with enhanced efficiency